Atlatl Advisers LLC Decreases Stake in Haleon PLC Sponsored ADR $HLN

Atlatl Advisers LLC reduced its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 3.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,017 shares of the company’s stock after selling 1,515 shares during the period. Atlatl Advisers LLC’s holdings in Haleon were worth $394,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Brighton Jones LLC acquired a new position in Haleon during the fourth quarter worth about $187,000. Wealth Enhancement Advisory Services LLC increased its stake in shares of Haleon by 18.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 94,748 shares of the company’s stock worth $975,000 after purchasing an additional 14,935 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in shares of Haleon by 11.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 25,362 shares of the company’s stock worth $261,000 after purchasing an additional 2,564 shares during the last quarter. Golden State Wealth Management LLC lifted its stake in Haleon by 1,814.1% in the 1st quarter. Golden State Wealth Management LLC now owns 25,094 shares of the company’s stock valued at $258,000 after buying an additional 23,783 shares in the last quarter. Finally, PDS Planning Inc grew its holdings in Haleon by 8.0% during the 1st quarter. PDS Planning Inc now owns 21,645 shares of the company’s stock valued at $223,000 after buying an additional 1,598 shares during the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on HLN shares. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a report on Saturday. Barclays lowered shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. Wall Street Zen lowered shares of Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Finally, The Goldman Sachs Group upgraded shares of Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Trading Down 1.3%

Shares of HLN stock opened at $9.25 on Friday. The firm has a market cap of $41.17 billion, a P/E ratio of 23.71, a PEG ratio of 2.70 and a beta of 0.20. Haleon PLC Sponsored ADR has a 1-year low of $8.71 and a 1-year high of $11.42. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. The firm’s 50-day simple moving average is $9.38 and its 200-day simple moving average is $9.98.

Haleon Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Stockholders of record on Friday, August 15th were issued a dividend of $0.0555 per share. This represents a dividend yield of 190.0%. The ex-dividend date was Friday, August 15th. This is an increase from Haleon’s previous semi-annual dividend of $0.05. Haleon’s payout ratio is currently 28.21%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.